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The prevalence of hepatitis B virus (HBV) infection and human immunodeficiency virus
(HIV) infection in Mozambique is one of the highest in the world, though in spite of this the
prevalence of occult hepatitis B infection (OBI) is unknown.
Objectives
This study was conducted with the aim to investigate the prevalence of OBI and frequency
of isolated hepatitis B core antibody (anti-HBc alone) among antiretroviral (ART) naïve HIV-
positive patients in Mozambique.
Methods
A cross-sectional study was conducted in two health facilities within Maputo city. All ART-
naive HIV seropositive patients attending outpatient clinics between June and October 2012
were consecutively enrolled. Blood samples were drawn from each participant and used for
serological measurement of HBV surface antigen (HBsAg), antibodies against HBV surface
antigen (anti-HBs) and antibodies against core antigen (anti-HBc) using ELISA. Quantifica-
tion of HBV DNA was performed by real time PCR. A questionnaire was used to obtain
demographics and clinical data.
Results
Of the 518 ART-naive HIV-positive subjects enrolled in the study, 90.9% (471/518) were
HBsAg negative. Among HBsAg negative, 45.2% (213/471) had isolated anti-HBc antibod-
ies, and the frequency of OBI among patients with anti-HBc alone was 8.3% (17/206). OBI
was not correlated either with CD4+ T cells count or transaminases levels. A total of 11.8%
of patients with OBI presented elevated HBV DNA level. Frequency of individuals with APRI
score > 2 and FIB-4 score > 3.25 was higher in patients with OBI as compared not exposed,
immune and anti-HBc alone patients.
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Conclusion
Our data demonstrate for the first time that OBI is prevalent among HIV patients in Mozam-
bique, and will be missed using the commonly available serological assays that measures
HBsAg.
Introduction
Occult hepatitis B virus (HBV) infection (OBI) is defined as persistence of HBV DNA in the
liver (with or without HBV DNA in serum) in the absence of detectable HBV surface antigen
(HBsAg) [1]. In these patients, serum HBV DNA level is usually very low, mostly below 104
IU/mL. The clinical implications of OBI are not fully understood, but include: i) risk of HBV
transmission through blood transfusion, hemodialysis, organ and bone marrow transplanta-
tion, and perinatal route due to the hidden status of HBV infection; ii) hepatitis B virus reacti-
vation (HBVr) after immunosuppression; iii) risk of progression to chronic liver disease
(CLD); iiii) risk of development of hepatocellular carcinoma (HCC) [1].
The underlying mechanism leading to the absence of HBsAg in presence of HBV is not
completely understood. However, several mechanisms such as: 1./ presence of a strong
humoral and cellular immune response against HBV envelope proteins, leading to a low level
of HBV replication and low level of HBsAg expression; 2./ escape mutations in the S gene lead-
ing to lack of detection of the virus using HBsAg assays; 3./ infection with a mutant virus with
defective replication; 4./ formation of HBsAg/anti-HBs immunocomplexes which prevent
detection of HBsAg. and 5./ integration of HBV genome into the host chromosomes, infecting
peripheral mononuclear cells (monocytes and lymphocytes) that works as reservoirs. Finally,
the coinfections with other viruses such as hepatitis C virus (HCV) and human immunodefi-
ciency virus (HIV), or administration of drugs, including antiretrovirals, can also interfere
with the HBV replication and its pathogenic features[1–4]. OBI reactivation sometimes occurs
during an immunosuppression status (i.e., hematologic malignancies, chemo- or immunother-
apies, hematopoietic stem cell transplantation, or HIV infection).
Several studies have shown that the frequency of OBI is higher in HIV infected as compared
to HIV negative individuals, ranging between 0% and 89.5% [5–7]. The clinical impact of OBI
in HIV-infected subjects is still controversial [8], but several authors suggests that the risk of
hepatic flares, hepatic failure and liver cirrhosis or hepatic carcinoma is higher among these
patients [1, 7–10]. Current World Health Organization (WHO) guidelines recommends that
all HIV infected patients should be routinely screened for HBV and antiretroviral treatment
(ART) should be initiated immediately to those co-infected with HBV, irrespective of their
CD4+ T cells count [11]. Detection of serum HBV DNA using highly specific and sensitive
nucleic acid amplification test (NAAT) is the recommended method for detection of HBV
infection in clinical practice [12]. However, HBV NAAT is not available in limited resource
settings, including sub-Saharan Africa, where detection of HBsAg is the most commonly used
and available method for HBV screening. In this context, most HIV infected patients with OBI
will remain undetected, which will severely compromise their care [13]. The presence of anti-
HBc alone (defined as presence of anti-HBc antibodies in absence of other serological marker
of HBV) is considered a less than ideal predictor of OBI [1] and in places where availability of
molecular tests is very limited, anti-HBc has been used to prioritize samples that could be fur-
ther tested by PCR [1, 13]. However, accuracy of anti-HBc alone to identify OBI had been a
matter of debate as false anti-HBc positivity and negativity in the detection of OBI has been
previously reported [14] and described in the Taormina statement as well [1].
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In Mozambique, which has the eighth highest HIV prevalence in the world [15], the most
recent HIV survey showed that the epidemics is getting even worse [16]. Few studies have
been conducted to determine the prevalence of HBV in Mozambique, and they have been con-
ducted in specific groups such as refugees [17], blood donors [18–20], HIV infected individu-
als [21, 22] or high risk groups [23] and showed that the rate varied between 7% and 13%. OBI
has received new attention as a serious public health problem. However, no study has yet been
conducted in Mozambique to investigate the epidemiology and clinical implication of OBI.
Lack of data on OBI represents a major challenge to the implementation of interventions to
prevent complications of co-infection. This study was conducted with the aim to investigate
the frequency and clinical and laboratory characteristics of OBI in ART naïve HIV infected
patients in Maputo city. This study uses the same cohort of patients of our recently published
manuscript on the frequency and characteristics of HBV/HIV co-infection in Maputo [22].
Material and methods
Setting and population
A cross-sectional study was carried out between June and October 2012 in two public health
centers from Maputo city, Mozambique. During the study period, all ART-naive HIV positive
patients attending their routine follow up visits were consecutively invited to participate in this
study. All participants were informed of the study and consented prior to enrollment. Inclu-
sion criteria included age more than 18 years old and no prior history of ART. All pregnant
women were excluded. All participants were assigned a unique study identification code with
subsequent data collected and analyzed. The study was approved by the National Bioethics
Committee in Mozambique (Ref#: 82/CNBS/12). All investigation had been conducted
according to the principles expressed in Declaration of Helsinki. Oral and written informed
consents were obtained from all patients or their legal guardians.
Sample collection and testing
From each participant, a total of 10 ml of whole blood was collected into 5 ml of Vacuum tube
with K3EDTA and 5 mL of serum separation Vacuum tube (both from BD Vacutainer, USA). Full
blood counting was performed using an automated hematology analyzer (Sysmex KX21N: Sysmex
Corporation, Japan). Serum transaminases were measured using a clinical chemistry analyzer
(ABX pentra 400: Horiba ABX SAS, France). CD4+ T cells count was measured by flow cytometer
using a lyse-no wash protocol with MultiTest reagents and FACSCalibur flow cytometer (all from
Becton Dickinson, CA, USA). Testing for Hepatitis B was performed following the algorithm
depicted in Fig 1. All patients were screened for HBsAg using a immunochromatographic rapid
test with a sensitivity and specificity of 95.16% and 99.95% (Determine, Allere, Japan) and those
with negative HbsAg result were subsequently tested for anti-HBs and anti-HBc antibodies using
commercially available Enzyme Linked Immunoabsorbent Assay (ELISA) (Diasorin S.p.A., Sallu-
gia, Italy). Due to limitation of resources, HBV DNA was prioritized and measured in all patients
who were HBsAg negative, anti-HBs negative and anti-HBc positive (anti-HBc alone), using the
AmpliPrep/cobas TaqMan HBV test, v2.0 (Roche Diagnostics, Germany) with a limit of detection
of 20 IU/mL. In this context, OBI was defined as presence of HBV DNA in patients with serologi-
cal profile of anti-HBc alone (HBsAg negative, anti-HBs negative and anti-HBc positive).
Questionnaire
A questionnaire was used to collect socio-demographic characteristics, and clinical history
from each participant (See S1 File).
Occult hepatitis B infection in HIV infected individuals in Mozambique
PLOS ONE | https://doi.org/10.1371/journal.pone.0190775 January 10, 2018 3 / 10
Statistical analysis
Data was double entered in a database developed using Microsoft Access 2007. Analysis was
performed using the statistics package STATA 12.0 (StataCorp, College Station, TX, USA). For
our analysis, HBsAg negative patients were stratified into four groups according to a combina-
tion of HBV serological and molecular markers: i) Group A–anti-HBs negative and anti-HBc
negative (not exposed); ii) Group B–anti-HBs positive and anti-HBc positive (exposed and
immune); iii) Group C–anti-HBs negative, anti-HBc positive and HBV DNA< 20 UI/mL
(anti-HBc alone with HBV DNA< 20 UI/mL), and iv) Group D–anti-HBs negative, anti-HBc
positive and viral load >20UI/mL (occult hepatitis B).
We calculated the scores of FIB-4 (Fibrosis 4 index) and APRI (AST-Platelet Ratio Index)
to predict significant fibrosis and cirrhosis. These non-invasive serum biomarkers were calcu-
lated using the formula described previously [24]. As per WHO guidelines, an APRI
score > 2.0 indicates significant liver fibrosis and cirrhosis, while a FIB-4 score > 3.25 indi-
cates significant cirrhosis [11].
For univariate analysis, the Mann-Whitney U test was used to compare numerical variables
and Pearson’s chi-square test was used to compare categorical variables.
Results
The study population consisted of 518 HIV-infected patients with a median age of 33 years
old, 67.0% were female, and the median CD4+ T cells count was 362 cells/mm3. Among them,
Fig 1. Flowchart of recruitment and testing of study participants. anti-HBc- − antibody against HBV core antigen.
anti-HBs- − antibody against HBV surface antigen. DNA–desoxirribonucleic acid. HBsAg- HBV surface antigen.
HBV–hepatitis B virus. HIV–human immunodeficiency virus. OBI- occult hepatitis B virus infection.
https://doi.org/10.1371/journal.pone.0190775.g001
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47 (9.1%) were HBsAg positive, and 471 (90.9%) were HBsAg negative. Among the HBsAg
negative, 26.1% (123/471) were anti-HBs and anti-HBc negative (Group A–not exposed),
21.7% (102/471) were anti-HBs and anti-HBc positive (Group B–exposed and immune),
45.2% (213/471) were anti-HBs negative and anti-HBc positive (anti-HBc alone) and 7.0% (33/
471) were anti-HBs positive and anti-HBc negative (vaccinated). The last group was excluded
from our analysis. (See Fig 1).
Demographic, clinical and laboratorial characteristic of the study groups are presented in
the Table 1. We noted that there was a female dominance in all study groups, and the median
age was similar among all groups. Clinical signs of liver disease (jaundice, ascites, splenomeg-
aly and hepatomegaly) were not observed in any groups (See S2 File). We noted that the strati-
fication by WHO clinical stage was similar for all groups. All groups were also similar in terms
of laboratory findings, such as total leukocytes, total lymphocytes and CD4+ T cells counts.
HBV DNA quantification was performed in a total of 206 anti-HBc alone patients (seven
samples were excluded due to poor quality), of which 17 were HBV DNA positive, yielding a
prevalence of 8.3% (Group D–OBI). The remaining 189 (40.1%) had an undetectable serum
level of HBV DNA (anti-HBc alone with HBV DNA < 20 UI/mL) (Fig 1). In patients with
OBI, 64.7% (11/17), 23.5% (4/17) and 11.8% (2/17) had a viral load of 20–100 IU/mL, 101–
1000 IU/mL and > 1000 IU/mL, respectively (Table 2).
Table 1. Demographic, clinical and laboratorial characteristic in HIV patients with HBsAg negative.
Characteristic Group A Group B Group C Group D p-value









Total, n (%) 123 (26.1) 102 (21.7) 189 (40.1) 17 (8.3)
Female (%) 79 (64.8) 63 (62.4) 128 (68.1) 13 (76.5) 0.567
Median age, years (IQR) 32 (27–41) 35 (29–42) 35 (28–43) 31 (27–39) 0.428
WHO clinical stage (%)
Stage I 55 (45.5) 37 (37.4) 93 (50.3) 5 (31.3) 0.535
Stage II 34 (28.1) 33 (33.3) 55 (29.7) 6 (37.5)
Stage III 30 (24.8) 29 (29.3) 36 (19.5) 5 (31.3)
Stage IV 2 (1.7) 0 (0.0) 1 (0.6) 0 (0.0)
ALT (IU/L) (IQR) 21,8 (16.5–30.7) 21,4 (14.6–30.1) 21,7 (16.6–30.9) 24,7 (16.6–49.7) 0.493
APRI
< = 2.0 121 (98.4) 99 (98.0) 187 (98.9) 14 (87.5) 0.017
>2.0 2 (1.6) 2 (2.0) 2 (1.1) 2 (12.5)
FIB-4
< = 3.25 120 (98.4) 98 (98.0) 187 (99.5) 15 (93.7) 0.309
>3.25 2 (1.6) 2 (2.0) 1 (0.5) 1 (6.3)
Leucocyte count (103 cells/mm3)
(IQR)
4,7 (3.8–5.7) 4,5 (3.7–5.5) 4,8 (3.8–5.8) 4,3 (3.7–5.3) 0.581
Lymphocyte count (103 cells/mm3)
(IQR)
2 (2–2) 2 (1–2) 2 (1–2) 2 (1–2) 0.190
CD4+T cell count (cells/mm3)
(IQR)
391 (211–538) 322 (204–477) 355 (202–517) 334 (86–543) 0.457
ALT–alanine aminotransferase; anti-HBc−− antibody against HBV core antigen; anti-HBs−− antibody against HBV surface antigen; CD4+ T–lymphocyte T with CD4+
phenotype; DNA–desoxirribonucleic acid; HBsAg–HBV surface antigen; HBV–hepatitis B virus; HIV–human immunodeficiency virus; IQR–interquartile range; IU/L–
International Units per litre; OBI–occult hepatitis B virus infection; WHO–World Health Organization
https://doi.org/10.1371/journal.pone.0190775.t001
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Discussion
In this study we used the same cohort of HIV infected patients of our recently published man-
uscript on HIV/HBV co-infection [22] to further investigate occurrence of OBI, and we found
a prevalence of OBI of 8.3% in anti-HBc alone HIV infected patients, which was similar to that
reported in other studies, but higher and lower frequencies had also been described elsewhere
[25–31]. The differences in the prevalence of OBI in different studies might be attributed to: i)
differences in the epidemiology of both viruses, ii) differences in limit detection of different
PCR assays, iii) differences in the study design and iv) differences in the definition criteria of
OBI in different studies [9, 31]. We acknowledge that our criteria of OBI may have led to
under or over estimation of OBI, because current OBI definition criteria recommend serial
testing per patient and use of PCR assays targeting two different HBV genomic places. How-
ever, due to a lack of resources, in this study only patients with anti-HBc alone patients were
tested and we used a PCR assay targeting only one place of HBsAg gene which was tested in
only one sample per patient. This algorithm could have missed some cases and we acknowl-
edge this as a limitation of our study.
To our knowledge this represents the first report of OBI in Mozambique and demonstrates
that OBI is prevalent among HIV/HBV co-infected Mozambicans, suggesting that presence of
HBV infection among HIV infected individuals will not be identified in a significant number
of co-infected patients when screened using the routinely used serological tests based on mea-
surement of HBsAg. Of note, if we add the number of patients with OBI (n = 17) reported in
this study with those already known to be HBV positive, based on measurement of HBsAg
who were reported in our previous publication using this cohort of patients (n = 47) [22], we
conclude that the more accurate number of HBV infected patients in this group of patients is
64, corresponding to a prevalence of HBV of 12.4% (64/518) and not 9.1% (47/518) as reported
in our recent publication. In summary, use of HBV DNA increased the prevalence of HBV in
3.3%.
The clinical impact of OBI among HIV-infected patients is still unclear, but hepatic flares
and even fatal reactivation of HBV infection following severe immunodeficiency and/or lami-
vudine withdrawal have been described in HIV co-infected patients [7, 32, 33]. Concern for
potential negative impact of persistent OBI among HIV infected patients in Mozambique has
received new attention given the high prevalence of HBV and HIV [16]. Indeed the prevalence
of HIV in Mozambique increased from 11.5% in 2009 to 13.2% in 2015 and represents one of
the worst epidemics in the world [16].
The frequency of anti-HBc alone found in this study was 45.2% (213/471), similar to that
reported among blood donors in Mozambique [20]. However only 8.3% of these patients had
OBI, showing a weak value of this serological marker to predict OBI. However, if we consider
Table 2. Serum viral load (DNA of HBV) in 17 HIV patients, with occult hepatitis B infection.




DNA–desoxirribonucleic acid; HBV–hepatitis B virus; HIV–human immunodeficiency virus; IU/mL–International
Units per milliliter; Compared to other groups, patients with OBI presented a higher frequency of APRI score >2
(12.5% in OBI versus 1.6% in not-exposed, 2.0% in immune and 1.1% in anti-HBc alone, p-value = 0.017) and FIB-4
score > 3.25 (6.3% in OBI versus 1.6% in not-exposed, 2.0% in immune and 0.5% in anti-HBc alone, p-
value = 0.309).
https://doi.org/10.1371/journal.pone.0190775.t002
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that more than 1.5 million of people are infected by HIV in Mozambique, it is unlikely that
molecular testing could be offered routinely for such a large number of HIV infected patients
and the use of anti-HBc alone in the absence of molecular testing may overestimate the preva-
lence of HBV (given that 45% had anti-HBc but only 8% had detectable DNA).
CD4+ T cells count was similar in all study groups, which corroborates finding from previ-
ous studies that showed no association between CD4+ T cells count and OBI in HIV patients
[34].
Our data shows that most HIV infected patients with OBI had a low viremia, which was not
surprising as low viremia is a hallmark of OBI [3] and similar findings were reported in other
countries [5, 9, 26, 34]. In OBI, viremia is considered low due to different factors including a
viral suppression resulting from strong host response occurring during acute or chronic infec-
tion [35]. Notably, 11.8% of patients with OBI had HBV DNA levels,> 1,000 copies/mL, rep-
resenting a group of patients at higher risk of deterioration of liver disease as previously shown
[36]. As in other studies, there was no evidence of high alanine aminotransferase (ALT) levels
in patients with OBI [26, 37]. Of note, frequency of patients with significant fibrosis according
to measurement of APRI and FIB-4 scores was higher in patients with OBI, however, due to
the transversal design of our study we are unable to conclude that HIV infected patients with
OBI are at high risk of progressing to liver disease. Current data on the impact of OBI in liver
disease in HIV infected are inconclusive [1] with some showing higher risk of hepatic flares [7]
and other showing no impact [25, 34]. This highlight that longitudinal studies are urgently
needed to address this issue. However, administration of ART regimens containing TDF plus
3TC or FTC in immunosuppressed patients with OBI is considered the most effective inter-
vention for long term prevention of liver inflammation [9]. Mozambique has endorsed the
WHO recommendation for immediate initiation of ART in patients co-infected with HIV and
HBV, and discussion for the routine testing of HBsAg in all HIV infected patients are ongoing.
However, we anticipate that a significant number of HIV patients who have OBI will not be
identified using the routinely available serological assays for detection of HBV in limited
resource settings, which is the HBsAg marker. Consequently, these patients may be falsely clas-
sified as negative using HBsAg detection alone and subsequently at risk for unresolved HBV
infection and liver inflammation [5, 9, 26, 27]. Moreover, it is less likely that molecular screen-
ing of HBV will be routinely available in many developing countries in the near future, includ-
ing in Mozambique.
Most of participants in this study were female, which is not surprising as is well known that
women attend more frequently health facilities as compared to men.
We would like to acknowledge additional limitations of our study. First, we acknowledge a
lack of severely immunosuppressed HIV patients in our sample, which did not allow us to
understand the profile of OBI in these patients and the transversal design of our study limited
our ability to determine the impact of OBI in the progression to liver disease. Second, we
acknowledge that the limit of detection of our assay did not allow us to detect presence of virus
with viral load below 20 UI/ml. Lastly, sequencing and genotyping of HBV from patients with
OBI was not performed due to a lack of resources, for this reason we are not able to ascertain if
there are genetic difference in the genome of the virus from infected patients with and without
OBI.
Conclusion
Our study demonstrated that OBI is prevalent among HIV infected patients in Mozambique,
suggesting that a significant number of HIV infected patients who are co-infected with HBV
will not be identified using commonly used serological assays. This potentially could be a
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reason for missing an opportunity for immediate initiation of ART. The presence of HBV
DNA level in 11.8% and higher frequencies of significant fibrosis and cirrhosis in patients with
OBI, suggests that these patients are at higher risk of progression to liver disease. In conclu-





S2 File. Clinical signs of liver disease in HIV patients with HBsAg negative.
(XLS)
Acknowledgments
We thank all participants and staff of all participating sites, for their valuable contribution.
We also thank the staff members of the Polana Caniço Health and Training Center (CIS-
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